We use cookies to give you the best online experience. By using our website, you agree to our use of cookies in accordance with our privacy policy.

×

Drive the future of chronic insomnia treatment.

Pear Therapeutics is proud to introduce Somryst, the only FDA-authorized prescription digital therapeutic (PDT) that delivers cognitive behavioral therapy for insomnia (CBT-I) to treat chronic insomnia by improving the insomnia symptoms of patients who are 22 years of age or older.

Why Somryst?

Somryst is the first FDA-authorized PDT that treats chronic insomnia by improving the insomnia symptoms of patients who are 22 years of age or older. Somryst uses an app to deliver CBT-I, which is recommended as first-line treatment for all adults with chronic insomnia.1 By delivering treatment digitally, Somryst makes CBT-I accessible for anyone, anywhere.

In clinical trials over the course of 9 weeks, the therapeutic equivalent of Somryst delivered2-4*:

Check mark

A sustained decline in insomnia symptom severity for most patients

Check mark

No drug-induced side effects or dependency risk

Check mark

Improvements that lasted up to 12 months for most patients, with many of them no longer meeting the clinical threshold for chronic insomnia

*Somryst was tested under the name Sleep Healthy Using the Internet (SHUTi), an early version of Somryst with equivalent content. In clinical studies, Somryst demonstrated persistent results at 6- and 12-month follow-ups. Somryst users may not experience any or all of these benefits.5

What are PDTs?

PDTs are a new class of therapeutics that use digital tools and software to treat serious diseases, ranging from insomnia to addiction. They are clinically validated, and unlike pharmaceutical treatments, they don’t come with a risk of dependency or drug-induced side effects.

They differ from health and wellness apps and wearable devices in that they are validated and authorized by the FDA, prescribed by a physician, and backed by clinical data.

At Pear Therapeutics, we see PDTs as an opportunity to deliver the best care possible. We’re leading the way in the emerging field of digital health with 2 other PDTs already helping patients.

Thank you!

We’ll be in touch soon with more information.

Stay up to date

All fields are required

References: 1. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; for the Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125-133. 2. Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. Lancet Psychiatry 2016; 3:(4)‍333-341. 3. Batterham PJ, Christensen H, Mackinnon A, et al. Trajectories of change and long-term outcomes in a randomized controlled trial of internet-based insomnia treatment to prevent depression. BJPsych Open. 2017;3(5):228-235. doi:10.1192/bjpo.bp.117.005231. 4. Ritterband LM, Thorndike FP, Ingersoll KS, et al. Effect of a web-based cognitive behavior therapy for insomnia intervention with 1-year follow-up: a randomized clinical trial. JAMA Psychiatry. 2017;74(1):68-75. 5. Somryst Clinician Direction for Use.

Indications for Use

Somryst is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (Cognitive Behavioral Therapy for Insomnia — CBT-I) to patients 22 years of age and older with chronic insomnia. Somryst treats patients with chronic insomnia by improving a patient’s insomnia symptoms.

Who Should Not Use Somryst (Contraindications)

Somryst uses sleep restriction and consolidation, limiting the time a patient spends in bed to match the amount of time they sleep. This treatment technique can increase risks to some patients whose pathophysiology may be worsened. Because of this, it is not appropriate for everyone. Patients with the following conditions or disorders should not use Somryst:

Important Safety Information for Clinicians:

Somryst is not for everyone. Please use your clinical judgement to determine whether Somryst is right for your patient.

Note: In the early stages of treatment, increased daytime sleepiness may be expected, but is usually temporary. Please consult with your Health Care Provider if these experiences do not go away over a few weeks, as it may indicate that you may have another sleep disorder or medical condition other than insomnia. If you have trouble staying awake while performing potentially dangerous tasks (like driving) at any point in the treatment, to avoid these dangerous tasks or stop following the sleep restriction component of the therapy.

Please see the Clinician Brief Summary Instructions for Somryst.